___

• Gyawali S, Sharma P, Mahapatra A. Meningioma and psychiatric symptoms: an individual patient data analysis. Asian journal of psychiatry. 2019;42:94-103.
• TURNOG- Türk Nöroşirürji Derneği Nöroonkolojik Cerrahi Öğretim ve Eğitim Grubu https://www.turnog.com/turnogDATA/ userfiles/file/Meningiomlar.pdf (21.10.2021).
• Buerki RA, Horbinski CM, Kruser T, Horowitz PM, James CD, Lukas RV. An overview of meningiomas. Future Oncology. 2018;14(21):2161-2177.
• Katar S, Baran O, Evran S, Cevik S, Akkaya E, Baran G et al. Expression of miRNA-21, miRNA-107, miRNA-137 and miRNA- 29b in meningioma. Clinical neurology and neurosurgery. 2017;156:66-70.
• Söylemezoğlu F. Meningiom sınıflaması ve histopatolojik özellikleri. Türk Nöroşirürji Dergisi. 2011;21:84-90.
• Murnyák B, Bognár L, Klekner Á, Hortobágyi T. Epigenetics of meningiomas. BioMed research international. 2015;2015:532451.
• Galani V, Lampri E, Varouktsi A, Alexiou G, Mitselou A, Kyritsis AP. Genetic and epigenetic alterations in meningiomas. Clinical neurology and neurosurgery. 2017;158:119-125.
• Bondy M, Ligon BL. Epidemiology and etiology of intracranial meningiomas: A review. Journal of neuro-oncology. 1996;29(3):197-205.
• Gazzeri R, Galarza M, Gazzeri G. Growth of a meningioma in a transsexual patient after estrogen–progestin therapy. New England Journal of Medicine. 2007;357(23):2411-2412.
• Claus EB, Black PM, Bondy ML, Calvocoressi L, Schildkraut JM, Wiemels JL et al. Exogenous hormone use and meningioma risk: what do we tell our patients? Cancer: Interdisciplinary International Journal of the American Cancer Society. 2007;110(3):471- 476.
• Gil M, Oliva B, Timoner J, Maciá MA, Bryant V, de Abajo FJ. Risk of meningioma among users of high doses of cyproterone acetate as compared with the general population: evidence from a population‐based cohort study. British journal of clinical pharmacology. 2011;72(6):965-968.
• Nordenskjöld AC, Bujila R, Aspelin P, Flodmark O, Kaijser M. Risk of Meningioma after CT of the Head. Radiology. 2017;285(2):568-575.
• Carlberg M, Söderqvist F, Mild KH, Hardell L. Meningioma patients diagnosed 2007–2009 and the association with use of mobile and cordless phones: A case–control study. Environmental health. 2013;12(1):1-10.
• Connelly JM, Malkin MG. Environmental risk factors for brain tumors. Current neurology and neuroscience reports. 2007;7(3):208-214.
• Yuniarti H, Subagio HW, Puruhita N, Murbawani EA, Nugrohowati AK, Priambada D et al. Body Mass Index and Waist Hip Ratio as a Risk Factor for Meningioma Incidence. Current Nutrition & Food Science. 2021;17(7):782-788.
• Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. Journal of neuro-oncology. 2010;99(3):307-314.
• Çelik AO, Umul A, Demirtaş H. Radiological Appearence of Unique Cystic Degeneration in Secretory Meningioma. Causa- Pedia 2015;4:1273.
• Wang L, Chen S, Liu Y, Zhang H, Ren N, Ma R et al. The biological and diagnostic roles of MicroRNAs in meningiomas. Rev Neurosci. 2020 Oct 25;31(7):771-778
• Westphal M, Lamszus K. Circulating biomarkers for gliomas. Nat Rev Neurol. 2015;11(10):556-566.
• Schonberg DL, Lubelski D, Miller TE, Rich JN. Brain tumor stem cells: Molecular characteristics and their impact on therapy. Molecular aspects of medicine. 2014;39:82-101.
• Ergun S, Tayeb TS, Arslan A, Temiz E, Arman K, Safdar M et al. The investigation of miR-221-3p and PAK1 gene expressions in breast cancer cell lines. Gene. 2015;555(2):377-381.
• Bukhari SI, Truesdell SS, Vasudevan S. Analysis of MicroRNA-mediated translation activation of in vitro transcribed reporters in quiescent cells. Methods Mol Biol. 2018;1686:251-264.
• Reddy KB. MicroRNA (miRNA) in cancer. Cancer cell international. 2015;15(1):1-6.
• Tie Y, Liu B, Fu H, Zheng X. Circulating miRNA and cancer diagnosis. Sci China C Life Sci. 2009 Dec;52(12):1117-1122
• Reddy KB. MicroRNA (miRNA) in cancer. Cancer cell international. 2015;15(1):38.
• Ergun S, Arman K, Temiz E, Bozgeyik I, Yumrutaş Ö, Safdar M et al. Expression patterns of miR-221 and its target Caspase- 3 in different cancer cell lines. Molecular biology reports. 2014;41(9):5877-5881.
• Saydam O, Shen Y, Würdinger T, Senol O, Boke E, James MF et al. Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/β-catenin signaling pathway. Molecular and cellular biology.
• Redova M, Sana J, Slaby O. Circulating miRNAs as new blood-based biomarkers for solid cancers. Future oncology. 2013;9(3):387-402.
• Pardo O. Meningioma dissemination and growth: a role for microRNAs. Oncogene. 2015;34(14):1743-1744.
• Zhi F, Shao N, Li B, Xue L, Deng D, Xu Y et al. A serum 6-miRNA panel as a novel non-invasive biomarker for meningioma. Scientific reports. 2016;6:32067.
• Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. Corrigendum: MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011 Apr;13(4):423-433.
• Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell. 2007;129(7):1401-1414.
• Wang M, Deng X, Ying Q, Jin T, Li M, Liang C. MicroRNA-224 targets ERG2 and contributes to malignant progressions of meningioma. Biochemical and biophysical research communications. 2015;460(2):354-361.
• Kliese N, Gobrecht P, Pachow D, Andrae N, Wilisch-Neumann A, Kirches E et al. miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells. Oncogene. 2013;32(39):4712- 4720.
• Senol O, Schaaij-Visser T, Erkan E, Dorfer C, Lewandrowski G, Pham T et al. miR-200a-mediated suppression of non-muscle heavy chain IIb inhibits meningioma cell migration and tumor growth in vivo. Oncogene. 2015;34(14):1790-1798.
• Mitha R, Shamim MS. Significance of micro-RNA expression in patients with meningioma. JPMA The Journal of the Pakistan Medical Association. 2020;70(7):1287.
• Ludwig N, Kim Y-J, Mueller SC, Backes C, Werner TV, Galata V et al. Posttranscriptional deregulation of signaling pathways in meningioma subtypes by differential expression of miRNAs. Neuro-oncology. 2015;17(9):1250-1260.
• Heneghan HM, Miller N, Kelly R, Newell J, Kerin MJ. Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. The oncologist. 2010;15(7):673.